CDNA microarray analysis and immunohistochemistry reveal a distinct molecular phenotype in serous endometrial cancer compared to endometrioid endometrial cancer

Experimental and Molecular Pathology

Volumn 91, Issue 1, 2011, Pages 373-384

  Chen, Yonghua ^a   Yao, Yuanyang ^a   Zhang, Lili ^a   Li, Xiaoping ^a   Wang, Yue ^a   Zhao, Lijun ^a   Wang, Jianliu ^a   Wang, Gongwei ^a   Shen, Danhua ^a   Wei, Lihui ^a   Zhao, Jianqing ^b  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b CapitalBio Corporation   (China)

Author keywords

CDNA microarrays; Endometrioid adenocarcinoma; Immunohistochemistry; Serous adenocarcinoma

Indexed keywords

BUB1 RELATED PROTEIN; COMPLEMENTARY DNA; FUCOSYLTRANSFERASE; FUCOSYLTRANSFERASE 8; LIPOCORTIN 4; NDC80 COMPLEX; PUMA PROTEIN; UNCLASSIFIED DRUG;

ANNEXIN A4 GENE; ARTICLE; BCL 2 BINDING COMPONENT 3 GENE; BUB1 GENE; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DNA MICROARRAY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; FEASIBILITY STUDY; FEMALE; FUCOSYLTRANSFERASE 8 GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION SYSTEM; GENE IDENTIFICATION; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NDC80 GENE; ONCOGENE; PHENOTYPE; PROCESS DEVELOPMENT; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; REPRODUCIBILITY OF RESULTS;

EID: 79955917320     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2011.04.005     Document Type: Article

References (55)

1. Alkushi A., Köbel M., Kalloger S.E., et al. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int. J. Gynecol. Pathol. 2010, 29:343-350.
2. Berchuck A., Rodriguez G., Kinney R.B., et al. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am. J. Obstet. Gynecol. 1991, 164:15-21.
3. Bharadwaj R., Qi W., Yu H., et al. Identification of two novel components of the human NDC80 kinetochore complex. J. Biol. Chem. 2004, 279:13076-13085.
4. Bignotti E., Ravaggi A., Tassi R.A., et al. Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas. Br. J. Cancer 2008, 99:768-773.
5. Bokhman J.V. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 1983, 15:10-17.
6. Briese J., Schulte H.M., Bamberger C.M., et al. Expression pattern of osteopontin in endometrial carcinoma: correlation with expression of the adhesion molecule CEACAM1. Int. J. Gynecol. Pathol. 2006, 25:161-169.
7. Butsushita K., Fukuoka S., Ida K., et al. Crystal structures of sodium-bound annexin A4. Biosci. Biotechnol. Biochem. 2009, 73:2274-2280.
8. Cao Q.J., Belbin T., Socci N., et al. Distinctive gene expression profiles by cDNA microarrays in endometrioid and serous carcinomas of the endometrium. Int. J. Gynecol. Pathol. 2004, 23:321-329.
9. Clarke B.A., Gilks C.B. Endometrial carcinoma: controversies in histopathological assessment of grade and tumor cell type. J. Clin. Pathol. 2010, 63:410-415.
10. Felix A.S., Weissfeld J., Edwards R., et al. Future directions in the field of endometrial cancer research: the need to investigate the tumor microenvironment. Eur. J. Gynaecol. Oncol. 2010, 31:139-144.
11. Ferguson S.E., Olshen A.B., Viale A., et al. Stratification of intermediate-risk endometrial cancer patients into groups at high risk or low risk for recurrence based on tumor gene expression profiles. Clin. Cancer Res. 2005, 11:2252-2257.
12. Friedrichs K., Gluba S., Eidtmann H., et al. Overexpression of p53 and prognosis in breast cancer. Cancer 1993, 72:3641-3647.
13. Gao F., Ponte J.F., Levy M., et al. hBub1 negatively regulates p53 mediated early cell death upon mitotic checkpoint activation. Cancer Biol. Ther. 2009, 8:548-556.
14. Gao F., Ponte J.F., Papageorgis P., et al. hBub1 deficiency triggers a novel p53 mediated early apoptotic checkpoint pathway in mitotic spindle damaged cells. Cancer Biol. Ther. 2009, 8:627-635.
15. Getz G., Levine E., Domany E. Coupled two-way clustering analysis of gene microarray data. Proc. Natl. Acad Sci. U.S.A. 2009, 97:12079-12084.
16. Gout S., Huot J. Role of cancer microenvironment in metastasis: focus on colon cancer. Cancer Microenviron. 2008, 1:69-83.
17. Grabellus F., Sheu S.Y., Tötsch M., et al. Overexpression of the drug resistance-associated protein metallothionein does not correlate with response of sarcomas to isolated limb perfusion treatment. J. Surg. Oncol. 2010, 101:465-470.
18. Jeffers J.R., Parganas E., Lee Y., et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 2003, 4:321-328.
19. Kohler M.F., Berchuck A., Davidoff A.M., et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res. 1992, 52:1622-1627.
20. Lax S.F., Kurman R.J., Pizer E.S., et al. A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis. Am. J. Surg. Pathol. 2000, 24:1201-1208.
21. Liao B., Hu Y., Herrick D.J., et al. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J. Biol. Chem. 2005, 280:18517-18524.
22. Lukes A.S., Kohler M.F., Pieper C.F., et al. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 1994, 73:2380-2385.
23. Martin-Lluesma S., Stucke V.M., Nigg E.A. Role of Hec1 in spindle checkpoint signaling and kinetochore recruitment of Mad1/Mad2. Science 2002, 297:2267-2270.
24. Maxwell G.L., Chandramouli G.V., Dainty L., et al. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer. Clin. Cancer Res. 2005, 11:4056-4066.
25. Maxwell G.L., Risinger J.I., Alvarez A.A., et al. Favorable survival associated with microsatellite instability in endometrioid endometrial cancers. Obstet. Gynecol. 2001, 97:417-422.
26. Maxwell G.L., Risinger J.I., Hayes K.A., et al. Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers. Clin. Cancer Res. 2000, 6:2999-3005.
27. May F.E., Westley B.R. Expression of human intestinal trefoil factor in malignant cells and its regulation by oestrogen in breast cancer cells. J. Pathol. 1997, 182:404-413.
28. Mhawech-Fauceglia P., Wang D., Kesterson J., et al. Microarray analysis reveals distinct gene expression profiles among different tumor histology, stage and disease outcomes in endometrial adenocarcinoma. PLoS One 2010, 5:e15415.
29. Mita Y., Aoyagi Y., Suda T., et al. Plasma fucosyltransferase activity in patients with hepatocellular carcinoma, with special reference to correlation with fucosylated species of alpha-fetoprotein. J. Hepatol. 2000, 32:946-954.
30. Miyoshi E., Uozumi N., Noda K., et al. Expression of α1-6 fucosyltransferase in rat tissues and human cancer cell lines. Int. J. Cancer 1997, 72:1117-1121.
31. Moll U.M., Chalas E., Auguste M., et al. Uterine papillary serous carcinoma evolves via a p53-driven pathway. Hum. Pathol. 1996, 27:1295-1300.
32. Moreno-Bueno G., Sánchez-Estévez C., Cassia R., et al. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res. 2003, 63:5697-5702.
33. Mutter G.L., Baak J.P., Fitzgerald J.T., et al. Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. Gynecol. Oncol. 2001, 83:177-185.
34. Nakano K., Vousden K.H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 2001, 7:683-694.
35. Otto C., Rohde-Schulz B., Schwarz G., et al. In vivo characterization of progestins with reduced non-genomic activity in vitro. Ernst Schering Found. Symp. Proc. 2007, 1:151-170.
36. Petridou E., Koukoulomatis P., Alexe D.M., et al. Endometrial cancer and the IGF system: a case-control study in Greece. Oncology 2003, 64:341-345.
37. Ponnampalam A.P., Rogers P.A. Cyclic changes and hormonal regulation of annexin IV mRNA and protein in human endometrium. Mol. Hum. Reprod. 2006, 12:661-669.
38. Risinger J.I., Maxwell G.L., Chandramouli G.V., et al. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res. 2003, 63:6-11.
39. Saghir F.S., Rose I.M., Dali A.Z., et al. Gene expression profiling and cancer-related pathways in type I endometrial carcinoma. Int. J. Gynecol. Cancer 2010, 20:724-731.
40. Saidi S.A., Holland C.M., Kreil D.P., et al. Independent component analysis of microarray data in the study of endometrial cancer. Oncogene 2004, 23:6677-6683.
41. Sakwe A.M., Koumangoye R., Guillory B., et al. Annexin A6 contributes to the invasiveness of breast carcinoma cells by influencing the invasiveness of breast carcinoma cells by influencing the organization and localization of functional focal adhesions. Exp. Cell Res. 2010, 317:823-837.
42. Shah M., Telang S., Raval G., et al. Serum fucosylation changes in oral cancer and oral precancerous conditions. Cancer 2008, 113:336-346.
43. Smid-Koopman E., Blok L.J., Helmerhorst T.J., et al. Gene expression profiling in human endometrial cancer tissue samples: utility and diagnostic value. Gynecol. Oncol. 2004, 93:292-300.
44. Tashiro H., Blazes M.S., Wu R., et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997, 57:3935-3940.
45. Wong Y.F., Cheung T.H., Lo K.W., et al. Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling. Oncogene 2007, 26:1971-1982.
46. Yao Y., Chen Y., Wang Y., et al. Molecular classification of human endometrial cancer based on gene expression profiles from specialized microarrays. Int. J. Gynaecol. Obstet. 2010, 110:125-129.
47. Yee K.S., Wilkinson S., James J., et al. PUMA- and Bax-induced autophagy contributes to apoptosis. Cell Death Differ. 2009, 16:1135-1145.
48. Yemelyanova A., Ji H., Shih IeM, et al. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am. J. Surg. Pathol. 2009, 33:1504-1514.
49. Yu H., Tang Z. Bub1 multitasking in mitosis. Cell Cycle 2005, 4:262-265.
50. Yu J., Zhang L. No PUMA, no death: implications for p53-dependent apoptosis. Cancer Cell 2003, 4:248-249.
51. Zaino R.J. FIGO staging of endometrial adenocarcinoma: a critical review and proposal. Int. J. Gynecol. Pathol. 2009, 28:1-9.
52. Zannoni G.F., Vellone V.G., Arena V., et al. Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study. Virchows Arch. 2010, 457:27-34.
53. Zheng W., Cao P., Zheng M., et al. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Gynecol. Oncol. 1996, 61:167-174.
54. Zheng W., Yi X., Fadare O., et al. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am. J. Surg. Pathol. 2008, 32:304-315.
55. Zimmermann U., Balabanov S., Giebel J., et al. Increased expression and altered location of annexin IV in renal clear cell carcinoma: a possible role in tumour dissemination. Cancer Lett. 2004, 209:111-118.